Summary | |
---|---|
Symbol | CWC22 |
Name | CWC22 spliceosome-associated protein |
Aliases | KIAA1604; EIF4GL; fSAPb; NCM; functional spliceosome-associated protein b; CWC22 spliceosome-associated prot ...... |
Chromosomal Location | 2q31.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway |
Subcellular Location | Nucleus Nucleus speckle Note=Concentrates around speckles, which are sites of pre-mRNA synthesis and processing, where it colocalizes with EJC core proteins. |
Domain |
PF02847 MA3 domain |
Function |
Required for pre-mRNA splicing and for exon-junction complex (EJC) assembly. Hinders EIF4A3 from non-specifically binding RNA and escorts it to the splicing machinery to promote EJC assembly on mature mRNAs. Through its role in EJC assembly, required for nonsense-mediated mRNA decay. |
Biological Process |
GO:0000375 RNA splicing, via transesterification reactions GO:0000377 RNA splicing, via transesterification reactions with bulged adenosine as nucleophile GO:0000398 mRNA splicing, via spliceosome GO:0006397 mRNA processing GO:0008380 RNA splicing GO:0043484 regulation of RNA splicing GO:0048024 regulation of mRNA splicing, via spliceosome GO:0050684 regulation of mRNA processing GO:1903311 regulation of mRNA metabolic process |
Molecular Function | - |
Cellular Component |
GO:0005681 spliceosomal complex GO:0005684 U2-type spliceosomal complex GO:0016604 nuclear body GO:0016607 nuclear speck GO:0071006 U2-type catalytic step 1 spliceosome GO:0071012 catalytic step 1 spliceosome GO:0071013 catalytic step 2 spliceosome |
KEGG | - |
Reactome |
R-HSA-74160: Gene Expression R-HSA-72203: Processing of Capped Intron-Containing Pre-mRNA R-HSA-72172: mRNA Splicing R-HSA-72163: mRNA Splicing - Major Pathway |
Summary | |
---|---|
Symbol | CWC22 |
Name | CWC22 spliceosome-associated protein |
Aliases | KIAA1604; EIF4GL; fSAPb; NCM; functional spliceosome-associated protein b; CWC22 spliceosome-associated prot ...... |
Chromosomal Location | 2q31.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Literatures that report relations between CWC22 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells. |
There is no record. |
Summary | |
---|---|
Symbol | CWC22 |
Name | CWC22 spliceosome-associated protein |
Aliases | KIAA1604; EIF4GL; fSAPb; NCM; functional spliceosome-associated protein b; CWC22 spliceosome-associated prot ...... |
Chromosomal Location | 2q31.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets. |
> High-throughput Screening
[ TOP ]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statistical results of CWC22 in screening data sets for detecting immune reponses.
|
Summary | |
---|---|
Symbol | CWC22 |
Name | CWC22 spliceosome-associated protein |
Aliases | KIAA1604; EIF4GL; fSAPb; NCM; functional spliceosome-associated protein b; CWC22 spliceosome-associated prot ...... |
Chromosomal Location | 2q31.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders |
Points in the above scatter plot represent the expression difference of CWC22 in various data sets.
|
Points in the above scatter plot represent the mutation difference of CWC22 in various data sets.
|
Summary | |
---|---|
Symbol | CWC22 |
Name | CWC22 spliceosome-associated protein |
Aliases | KIAA1604; EIF4GL; fSAPb; NCM; functional spliceosome-associated protein b; CWC22 spliceosome-associated prot ...... |
Chromosomal Location | 2q31.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CWC22. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene. |
Summary | |
---|---|
Symbol | CWC22 |
Name | CWC22 spliceosome-associated protein |
Aliases | KIAA1604; EIF4GL; fSAPb; NCM; functional spliceosome-associated protein b; CWC22 spliceosome-associated prot ...... |
Chromosomal Location | 2q31.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CWC22. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CWC22. > Immunoinhibitor > Immunostimulator > MHC molecule |
Summary | |
---|---|
Symbol | CWC22 |
Name | CWC22 spliceosome-associated protein |
Aliases | KIAA1604; EIF4GL; fSAPb; NCM; functional spliceosome-associated protein b; CWC22 spliceosome-associated prot ...... |
Chromosomal Location | 2q31.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CWC22. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor |
Summary | |
---|---|
Symbol | CWC22 |
Name | CWC22 spliceosome-associated protein |
Aliases | KIAA1604; EIF4GL; fSAPb; NCM; functional spliceosome-associated protein b; CWC22 spliceosome-associated prot ...... |
Chromosomal Location | 2q31.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Distribution of CWC22 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype |
Summary | |
---|---|
Symbol | CWC22 |
Name | CWC22 spliceosome-associated protein |
Aliases | KIAA1604; EIF4GL; fSAPb; NCM; functional spliceosome-associated protein b; CWC22 spliceosome-associated prot ...... |
Chromosomal Location | 2q31.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Associations between CWC22 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade |
Summary | |
---|---|
Symbol | CWC22 |
Name | CWC22 spliceosome-associated protein |
Aliases | KIAA1604; EIF4GL; fSAPb; NCM; functional spliceosome-associated protein b; CWC22 spliceosome-associated prot ...... |
Chromosomal Location | 2q31.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Drugs targeting CWC22 collected from DrugBank database. |
There is no record. |